[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Saved in:
Bibliographic Details
Title: [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.
Authors: Walter T; Department of Medical Oncology, Hôpital Édouard Herriot, Lyon, France., Jann H; Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Ansquer C; Department of Nuclear Medicine, Centre Hospitalier Universitaire de Nantes, Nantes, France., Deshayes E; Department of Nuclear Medicine, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier University, Montpellier, France., Garcia-Carbonero R; Department of Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación IIS Imas12, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain., Teulé A; Department of Medical Oncology, Institut Català d'Oncologia, Barcelona, Spain., Baum RP; Department of Molecular Radiotherapy, Curanosticum Wiesbaden-Frankfurt, Wiesbaden, Germany., Verberne HJ; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, Netherlands., Ćwikła JB; Department of Cardiology and Internal Medicine, University of Warmia and Mazury, Olsztyn and GAMMED Centrum Diagnostyczno-Lecznicze, Warsaw, Poland., Srirajaskanthan R; Department of Gastroenterology, King's College Hospital, London, UK., de Mestier L; Department of Pancreatology and Digestive Oncology, Université Paris-Cité, Hôpital Beaujon (AP-HP), Clichy, France., Grana CM; Radiometabolic Therapy Unit, Division of Nuclear Medicine, Istituto Europeo di Oncologia IRCCS, Milan, Italy., Buck A; Department of Nuclear Medicine, Universitätsklinikum Würzburg, Würzburg, Germany., Hörsch D; Department of Internal Medicine, Gastroenterology and Endocrinology, Zentralklinik Bad Berka, Bad Berka, Germany., Pavel M; Department Medicine 1, Universitätsklinikum Erlangen and Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany., Dierickx LO; Department of Nuclear Medicine, Université Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, France., Michael M; Department of Medical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia., Strosberg J; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA., Kollár A; Department of Medical Oncology, Inselspital, Bern, University Hospital, University of Bern, Bern, Switzerland., Jimenez-Fonseca P; Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain., Rinke A; Department of Gastroenterology and Endocrinology, Universitätsklinikum Gießen und Marburg, Philipps-Universität Marburg, Marburg, Germany., Del Olmo-García M; Department of Endocrinology and Nutrition, Hospital Universitari i Politècnic La Fe, Valencia, Spain., Flaus A; Department of Nuclear Medicine, Hospices Civils de Lyon - Hôpital Louis Pradel, Lyon, France., Hernando J; Department of Medical Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, and Neuroendocrine and Endocrine Tumor Translational Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Kluge A; ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft, Dresden, Germany., Breuninger M; ITM Oncologics, Garching bei München, Germany., Melnyk S; ITM Oncologics, Garching bei München, Germany., Zhernosekov K; ITM Medical Isotopes, Garching bei München, Germany., Capdevila J; Department of Medical Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, and Neuroendocrine and Endocrine Tumor Translational Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain. Electronic address: jcapdevila@vhio.net.
Corporate Authors: COMPETE Investigator Team
Source: Lancet (London, England) [Lancet] 2026 Jul 18; Vol. 408 (10551), pp. 234-247. Date of Electronic Publication: 2026 Jul 02.
Publication Type: Journal Article; Clinical Trial, Phase III; Multicenter Study; Randomized Controlled Trial; Equivalence Trial
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(26)00604-5